From: Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Overall | All patients enrolled(N = 115) |
---|---|
Age, years | 53.53(±8.69) |
Data for front-line treatment in this study | |
 The tumor origin | |
  Ovary | 107 (93.0%) |
  Fallopian tube | 6 (5.2%) |
  Peritoneum | 1 (0.9%) |
  unknown | 1 (0.9%) |
 Pathologic histology type | |
  Serous Tumors | 108 (93.9%) |
  High-grade | 91 (84.3%) |
  Low-grade | 8 (7.4%) |
  Unknown | 9 (8.3%) |
  Mucinous Tumors | 1 (0.9%) |
  Endometrioid Tumors | 1 (0.9%) |
  Clear Cell Tumors | 4 (3.5%) |
  Mixed epithelial tumors | 1 (0.9%) |
 FIGO stage | |
  I | 1 (0.9%) |
  II | 4 (3.5%) |
  III | 97 (84.3%) |
  IIIA | 10 (10.3%) |
  IIIB | 10 (10.3%) |
  IIIC | 74 (76.3%) |
  Unknown | 3 (3.1%) |
  IV | 13 (11.3%) |
  IVA | 3 (23.1%) |
  IVB | 6 (46.2) |
  Unknown | 4 (30.7%) |
Primary cytoreductive surgery | 59 (51.3%) |
Interval cytoreductive surgery | 56 (48.7%) |
Residual disease | |
 Optimal cytoreductive surgery | |
  No gross residual disease (R0) | 50 (43.5%) |
  <1 cm but visible residual disease | 46 (40.0%) |
  Suboptimal cytoreductive | 16 (13.9%) |
  Unknown | 3 (2.6%) |
Previous chemotherapy cycles | |
  < 6 | 16 (13.9%) |
 6–9 | 92 (80.0%) |
  > 9 | 2 (1.7%) |
 Unknown | 5 (4.3%) |
The previous response status to platinum-based chemotherapy | |
 Platinum-refractory | 36 (31.3%) |
 Platinum-resistant relapse | 31 (27.0%) |
 Partially platinum- sensitive relapse | 48 (41.7%) |
Data before this study | |
CA125, U/ml | 183.90 (72.27–430.65; 6.00–7135.00) |
ECOG | |
 0 | 63 (54.8%) |
 1 | 46 (40.0%) |
 2 | 6 (5.2%) |